The impact of right ventricular function on prognosis in patients with stage III non-small cell lung cancer after concurrent chemoradiotherapy

被引:0
|
作者
Lu Chen
Jingjuan Huang
Weihua Wu
Shengjun Ta
Xiaoyi Xie
机构
[1] Shanghai Chest Hospital,Department of Ultrasound
[2] Shanghai Jiao Tong University,Department of Cardiology
[3] Shanghai Chest Hospital,Department of Ultrasound
[4] Shanghai Jiao Tong University,undefined
[5] Yan’an People’s Hospital,undefined
关键词
Right ventricle; Strain; Chemoradiotherapy; Non-small cell lung cancer;
D O I
暂无
中图分类号
学科分类号
摘要
Right ventricular (RV) impairment after cancer therapy-related cardiotoxicity and its prognostic implications in lung cancer have not been examined. The present research sought to evaluate RV structure, function, and mechanics in stage III non-small-cell lung cancer (NSCLC) before and after concurrent chemoradiotherapy (CCRT), and to explore the associations between RV impairments, radiation dose, and all-cause mortality. This prospective investigation included 128 inoperable NSCLC patients who were scheduled to receive CCRT. Echocardiographic examination and strain evaluation was performed at baseline and 6 months post-CCRT in all participants. Conventional RV dimensions revealed no significant changes post-CCRT. However, a reduction in RV free wall strain (RV-fwLS) was observed at 6 months post-CCRT (− 28.3 ± 4.6% vs. − 25.5 ± 4.8%, P < 0.001). The same was revealed for global RV longitudinal strain (RV-GLS) (− 23.4 ± 2.9% vs. − 20.2 ± 3.4%, P < 0.001). Pearson correlation showed that RV radiation mean dose was related with the percentage change in RV-fwLS (r = 0.303, P = 0.001) and RV-GLS (r = 0.284, P = 0.002). In multivariable analysis, the percentage change in RV-fwLS was an independent predictor of all-cause mortality (HR 1.296, 95% CI 1.202–1.428, P < 0.001). RV longitudinal strain is deteriorated at 6 months post-CCRT. The RV mechanics deterioration was associated with radiation dose and affected the long-term outcome of stage III NSCLC patients treated with CCRT.
引用
收藏
页码:1009 / 1017
页数:8
相关论文
共 50 条
  • [31] IMPACT OF PRETRETMENT LEUKOCYTOSIS ON PROGNOSIS IN LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH CONCURRENT CHEMORADIOTHERAPY
    Topkan, Erkan
    Parlak, Cem
    Guler, Ozan C.
    Pehlivan, Berrin
    Selek, Ugur
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S412 - S412
  • [32] IMPACT OF PRETRETMENT LEUKOCYTOSIS ON PROGNOSIS IN LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH CONCURRENT CHEMORADIOTHERAPY
    Topkan, Erkan
    Parlak, Cem
    Pehlivan, Berrin
    Ozyilkan, Ozgur
    Selek, Ugur
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S556 - S556
  • [33] Consolidation Chemotherapy After Concurrent Chemoradiotherapy in Patients With Stage III Non-Small-Cell Lung Cancer Reply
    Ahn, Jin Seok
    Park, Keunchil
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (07) : 768 - +
  • [34] Pneumonitis After Chemoradiotherapy and Adjuvant Durvalumab in Stage III Non-Small Cell Lung Cancer
    Edwards, Donna M.
    Sankar, Kamya
    Alseri, Aaren
    Jiang, Ralph
    Schipper, Matthew
    Miller, Sean
    Dess, Kathryn
    Strohbehn, Garth W.
    Moghanaki, Drew
    Ramnath, Nithya
    Green, Michael D.
    Bryant, Alex K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (04): : 963 - 970
  • [35] Factors Affect the Survival Time after Recurrence in Stage III Non-small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy
    Hamamoto, Y.
    Kataoka, M.
    Semba, T.
    Uwatsu, K.
    Sugawara, Y.
    Inoue, T.
    Sakai, S.
    Takahashi, T.
    Aono, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S470 - S470
  • [36] Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer
    Huang, Yiqing
    Zhao, Joseph J.
    Soon, Yu Yang
    Wong, Alvin
    Aminkeng, Folefac
    Ang, Yvonne
    Asokumaran, Yugarajah
    Low, Jia Li
    Lee, Matilda
    Choo, Joan R. E.
    Chan, Gloria
    Kee, Adrian
    Tay, Sen Hee
    Goh, Boon Cher
    Soo, Ross A.
    THORACIC CANCER, 2022, 13 (22) : 3152 - 3161
  • [37] Concurrent chemoradiotherapy for inoperable stage III non-small-cell lung cancer
    Robert MacRae
    Hak Choy
    Current Oncology Reports, 2003, 5 (4) : 313 - 317
  • [38] Sequential chemoradiotherapy versus concurrent chemoradiotherapy plus consolidation chemotherapy in unresectable stage III non-small cell lung cancer
    El-Shenshawy, H. M.
    Fathy, A.
    Eteba, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [39] Preoperative Concurrent Chemoradiotherapy of S-1/Cisplatin for Stage III Non-Small Cell Lung Cancer
    Yamaguchi, Masafumi
    Toyokawa, Gouji
    Ohba, Taro
    Sasaki, Tomonari
    Kometani, Takuro
    Hamatake, Motoharu
    Hirai, Fumihiko
    Taguchi, Kenichi
    Yamanaka, Takeharu
    Seto, Takashi
    Takenoyama, Mitsuhiro
    Sugio, Kenji
    Ichinose, Yukito
    ANNALS OF THORACIC SURGERY, 2013, 96 (05): : 1783 - 1789
  • [40] How can we optimise concurrent chemoradiotherapy for inoperable stage III non-small cell lung cancer?
    Bayman, Neil
    Blackhall, Fiona
    McCloskey, Paula
    Taylor, Paul
    Faivre-Finn, Corinne
    LUNG CANCER, 2014, 83 (02) : 117 - 125